Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

Sarepta Therapeutics, Inc. announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for its clinical trial application for Study SRP-1005-101, also known as INSIGHTT. SRP-1005 is an investigational small interfering RNA therapeutic for the treatment of Huntington’s Disease.